BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Koumbi L. Current and future antiviral drug therapies of hepatitis B chronic infection. World J Hepatol 2015; 7(8): 1030-1040 [PMID: 26052392 DOI: 10.4254/wjh.v7.i8.1030]
URL: https://www.wjgnet.com/1948-5182/full/v7/i8/1030.htm
Number Citing Articles
1
Soheil Tavakolpour, Hajar Sadat Mirsafaei, Somayeh Elkaei Behjati, Mojtaba Ghasemiadl, Meisam Akhlaghdoust, Shahnaz Sali. Toward cure chronic hepatitis B infection and hepatocellular carcinoma prevention: Lessons learned from nucleos(t)ide analogues therapyImmunology Letters 2017; 190: 206 doi: 10.1016/j.imlet.2017.08.003
2
Sina Feustel, Fabiola Ayón-Pérez, Ana Sandoval-Rodriguez, Roberto Rodríguez-Echevarría, Homero Contreras-Salinas, Juan Armendáriz-Borunda, L. V. Sánchez-Orozco. Protective Effects of Moringa oleifera on HBV Genotypes C and H Transiently Transfected Huh7 CellsJournal of Immunology Research 2017; 2017: 1 doi: 10.1155/2017/6063850
3
Ying Wang, Bairong Shen. Translational InformaticsAdvances in Experimental Medicine and Biology 2022; 1368: 21 doi: 10.1007/978-981-16-8969-7_2
4
Yachao Tao, Dongbo Wu, Lingyun Zhou, Enqiang Chen, Changhai Liu, Xiaoqiong Tang, Wei Jiang, Ning Han, Hong Li, Hong Tang. Hepatitis B Virus InfectionAdvances in Experimental Medicine and Biology 2020; 1179: 137 doi: 10.1007/978-981-13-9151-4_6
5
Mia Cahill, Chris Ontiveros. The Liver Meeting 2016EMJ Hepatology 2017; : 2 doi: 10.33590/emjhepatol/10312166
6
Cheng Peng, Mengji Lu, Dongliang Yang. CRISPR/Cas9-based tools for targeted genome editing and replication control of HBVVirologica Sinica 2015; 30(5): 317 doi: 10.1007/s12250-015-3660-x
7
Lukasz T. Olenginski, Solomon K. Attionu, Erica N. Henninger, Regan M. LeBlanc, Andrew P. Longhini, Theodore K. Dayie. Hepatitis B Virus Epsilon (ε) RNA Element: Dynamic Regulator of Viral Replication and Attractive Therapeutic TargetViruses 2023; 15(9): 1913 doi: 10.3390/v15091913
8
Iao-Fai Lam, Min Huang, Margaret Dah-Tysr Chang, Pei-Wun Yao, Yu-Ting Chou, Sim-Kun Ng, Ying-Lin Tsai, Yu-Chang Lin, Yun-feng Zhang, Xiao-yuan Yang, Yiu-Kay Lai. Identification of anti-HBV activities in Paeonia suffruticosa Andr. using GRP78 as a drug target on Herbochip®Chinese Medicine 2017; 12(1) doi: 10.1186/s13020-017-0132-2
9
KASL clinical practice guidelines for management of chronic hepatitis BClinical and Molecular Hepatology 2019; 25(2): 93 doi: 10.3350/cmh.2019.1002
10
Zhihao Zhang, Ping He, Yan Zhou, Xuhua Xie, Shuying Feng, Changyu Sun. Anti‑HBV effect of interferon‑thymosin α1 recombinant proteins in transgenic Dunaliella�salina in�vitro and in�vivoExperimental and Therapeutic Medicine 2018;  doi: 10.3892/etm.2018.6227
11
Xieer Liang, Rong Fan, Jian Sun, Javed Shaikh, Ankush Taneja, Subhajit Gupta, Kamal Hamed. Effect of Telbivudine Versus Other Nucleos(t)ide Analogs on HBeAg Seroconversion and Other Outcomes in Patients with Chronic Hepatitis B: A Network Meta-AnalysisAdvances in Therapy 2016; 33(4): 519 doi: 10.1007/s12325-016-0305-x
12
Fatima Akram, Hafiza Marium Waheed, Fatima Iftikhar Shah, Ikram ul Haq, Narmeen Nasir, Muhammad Tayyab Akhtar, Umar Farooq Gohar. Burgeoning therapeutic strategies to curb the contemporary surging viral infectionsMicrobial Pathogenesis 2023; 179: 106088 doi: 10.1016/j.micpath.2023.106088
13
Jelena Todoric, Laura Antonucci, Michael Karin. Targeting Inflammation in Cancer Prevention and TherapyCancer Prevention Research 2016; 9(12): 895 doi: 10.1158/1940-6207.CAPR-16-0209
14
M. H. Hyun, Y.‐S. Lee, J. H. Kim, J. H. Je, Y. J. Yoo, J. E. Yeon, K. S. Byun. Systematic review with meta‐analysis: the efficacy and safety of tenofovir to prevent mother‐to‐child transmission of hepatitis B virusAlimentary Pharmacology & Therapeutics 2017; 45(12): 1493 doi: 10.1111/apt.14068
15
Shu-Rong Xiao, Gui-Dan Xu, Wu-Jun Wei, Bin Peng, Yi-Bin Deng. Antiviral effects of hepatitis B virus S gene-specific anti-gene locked nucleic acid in transgenic miceWorld Journal of Clinical Cases 2018; 6(8): 183-191 doi: 10.12998/wjcc.v6.i8.183
16
Long Jianfei, Li Ling, Zhang Yu, Zhang Jiming, Wang Bin. Tooth loss associated with the use of tenofovir disoproxil fumarateJournal of Clinical Pharmacy and Therapeutics 2020; 45(6): 1478 doi: 10.1111/jcpt.13219
17
Uma S. Singh, Varughese A. Mulamoottil, Chung K. Chu. 2′‐Fluoro‐6′‐methylene carbocyclic adenosine and its phosphoramidate prodrug: A novel anti‐HBV agent, active against drug‐resistant HBV mutantsMedicinal Research Reviews 2018; 38(3): 977 doi: 10.1002/med.21490
18
Feipeng Xu, Hua Zhang, Jiamei Chen, Junyi Zhan, Ping Liu, Wei Liu, Shenglan Qi, Yongping Mu. Recent progress on the application of compound formulas of traditional Chinese medicine in clinical trials and basic research in vivo for chronic liver diseaseJournal of Ethnopharmacology 2024; 321: 117514 doi: 10.1016/j.jep.2023.117514
19
Nese Inan, Fehmi Tabak. Viral Hepatitis: Chronic Hepatitis B2018; : 71 doi: 10.1007/978-3-319-93449-5_7
20
Geanne da Silva Lobato, Ademilton Alves Farias, Alessandra Pereira da Silva, José Raul Rocha de Araújo Júnior. Drug treatment of chronic hepatitis b in Brazil: a reviewGastroenterology & Hepatology: Open Access 2021; 12(6): 182 doi: 10.15406/ghoa.2021.12.00483
21
Jiaqian Pan, Shuangmei Tong, Lei Kang, Jing Tang. New anti-hepatitis B virus drugs under development and evaluationCurrent Opinion in Infectious Diseases 2016; 29(6): 632 doi: 10.1097/QCO.0000000000000318
22
Rocío González Grande, Inmaculada Santaella Leiva, Susana López Ortega, Miguel Jiménez Pérez. Present and future management of viral hepatitisWorld Journal of Gastroenterology 2021; 27(47): 8081-8102 doi: 10.3748/wjg.v27.i47.8081
23
Pardis Mohammadi Pour, Sajad Fakhri, Sedigheh Asgary, Mohammad Hosein Farzaei, Javier Echeverría. The Signaling Pathways, and Therapeutic Targets of Antiviral Agents: Focusing on the Antiviral Approaches and Clinical Perspectives of Anthocyanins in the Management of Viral DiseasesFrontiers in Pharmacology 2019; 10 doi: 10.3389/fphar.2019.01207
24
Tai-Cheng Zhou, Feng-Wei Liu, Jing-Hua Fan, Si-Hang Zhang, Song-Qin Lv, Zhi-Yong Yu, Yan-Mei Zhang, Liang Zhang, Jia Wei. The association of the heterogeneity of HBV reverse transcriptase quasispecies with antiviral efficacy after treatment with nucleos(t)ide analogues for 10 yearsInfection, Genetics and Evolution 2021; 89: 104706 doi: 10.1016/j.meegid.2021.104706
25
Yang Zhang, Yi-Tong Wang, Jian-Xing Luo, Xiao-Yu Hu, Fang Yang, Wu Lin, Xiao Liang, Bing-Jie Zhao, Song Zhang, Yuan-Yuan Chen. Effect of WSP, a Chinese Herbal Formula, on Th17/Treg Ratio and HBeAg Seroconversion in Telbivudine-Treated HBeAg-Positive Chronic Hepatitis B Patients with High Baseline ALT Levels (20–30 Times the ULN)Evidence-Based Complementary and Alternative Medicine 2019; 2019: 1 doi: 10.1155/2019/7260369
26
Wattana Leowattana, Tawithep Leowattana. Chronic hepatitis B: New potential therapeutic drugs targetWorld Journal of Virology 2022; 11(1): 57-72 doi: 10.5501/wjv.v11.i1.57
27
Dipali M. Dhoke, Shriniwas S. Basaiyye, Pramod B. Khedekar. Development and characterization of L-HSA conjugated PLGA nanoparticle for hepatocyte targeted delivery of antiviral drugJournal of Drug Delivery Science and Technology 2018; 47: 77 doi: 10.1016/j.jddst.2018.06.006
28
Jinyu Zhang, Yi Zhang, Sushant Khanal, Dechao Cao, Juan Zhao, Xindi Dang, Lam Ngoc Thao Nguyen, Madison Schank, Xiao Y. Wu, Yong Jiang, Shunbin Ning, Ling Wang, Mohamed El Gazzar, Jonathan P. Moorman, Haitao Guo, Zhi Q. Yao. Synthetic gRNA/Cas9 ribonucleoprotein targeting HBV DNA inhibits viral replicationJournal of Medical Virology 2023; 95(7) doi: 10.1002/jmv.28952
29
Dmitry Kostyushev, Sergey Brezgin, Anastasiya Kostyusheva, Dmitry Zarifyan, Irina Goptar, Vladimir Chulanov. Orthologous CRISPR/Cas9 systems for specific and efficient degradation of covalently closed circular DNA of hepatitis B virusCellular and Molecular Life Sciences 2019; 76(9): 1779 doi: 10.1007/s00018-019-03021-8
30
Prakriti Sinha, Parul Sahu. Dynamics of Immune Activation in Viral Diseases2020; : 205 doi: 10.1007/978-981-15-1045-8_14
31
Blessing A Aderibigbe. Polymeric therapeutic delivery systems for the treatment of infectious diseasesTherapeutic Delivery 2017; 8(7): 557 doi: 10.4155/tde-2017-0008
32
Sonia Singh, Shiwangi Sharma, Himanshu Sharma. Naturally Occurring Herbs and their Bioactive Metabolites: Potential Targets and Signaling Pathways of Antiviral AgentsEndocrine, Metabolic & Immune Disorders - Drug Targets 2023; 23(12): 1505 doi: 10.2174/1871530323666230622122901
33
Qian Zhang, Da-Chuan Cai, Peng Hu, Hong Ren. Low-level viremia in nucleoside analog-treated chronic hepatitis B patientsChinese Medical Journal 2021; 134(23): 2810 doi: 10.1097/CM9.0000000000001793
34
Feilin Ge, Yan Yang, Zhaofang Bai, Lanlan Si, Xuemei Wang, Jia Yu, Xiaohe Xiao, Yan Liu, Zhigang Ren. The role of Traditional Chinese medicine in anti-HBV: background, progress, and challengesChinese Medicine 2023; 18(1) doi: 10.1186/s13020-023-00861-2
35
Joonho Jeong, Jung Woo Shin, Seok Won Jung, Eun Ji Park, Neung Hwa Park. Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysisClinical and Molecular Hepatology 2022; 28(2): 254 doi: 10.3350/cmh.2021.0314
36
Eunju Kim, Hyun Woong Lee, Soon Sun Kim, Eileen Yoon, Eun Sun Jang, Jong‐In Chang, Young Youn Cho, Gi Hyeon Seo, Hyung Joon Kim. Tenofovir disoproxil fumarate versus tenofovir alafenamide on risk of osteoporotic fracture in patients with chronic hepatitis B: A nationwide claims study in South KoreaAlimentary Pharmacology & Therapeutics 2023; 58(11-12): 1185 doi: 10.1111/apt.17716
37
Hong Kim, Seoung-Ae Lee, Bum-Joon Kim. X region mutations of hepatitis B virus related to clinical severityWorld Journal of Gastroenterology 2016; 22(24): 5467-5478 doi: 10.3748/wjg.v22.i24.5467
38
Mohammad Enamul Hoque Kayesh, Yutaka Amako, Md Abul Hashem, Shuko Murakami, Shintaro Ogawa, Naoki Yamamoto, Tatsuro Hifumi, Noriaki Miyoshi, Masaya Sugiyama, Yasuhito Tanaka, Masashi Mizokami, Michinori Kohara, Kyoko Tsukiyama-Kohara. Development of an in vivo delivery system for CRISPR/Cas9-mediated targeting of hepatitis B virus cccDNAVirus Research 2020; 290: 198191 doi: 10.1016/j.virusres.2020.198191
39
Jia‐Horng Kao, Tarik Asselah, Xiao‐Guang Dou, Kamal Hamed. Telbivudine therapy for chronic hepatitis B: A journey to identify super‐responders and to optimize treatment using the roadmap modelJournal of Gastroenterology and Hepatology 2017; 32(1): 73 doi: 10.1111/jgh.13512
40
Pobitra Borah, Sangeeta Hazarika, Mohamed A. Morsy, Manoj Goyal, Ashna Chettri, Katharigatta N. Venugopala, Viresh Mohanlall, Pratap Chandra Acharya, Pran Kishore Deb, Raghu Prasad Mailavaram. Medicinal Chemistry of Chemotherapeutic Agents2023; : 319 doi: 10.1016/B978-0-323-90575-6.00001-6
41
Ganesh Selvaraj Duraisamy, Dattatry Bhosale, Ivana Lipenská, Ivana Huvarova, Daniel Růžek, Marc P. Windisch, Andrew D. Miller. Advanced Therapeutics, Vaccinations, and Precision Medicine in the Treatment and Management of Chronic Hepatitis B Viral Infections; Where Are We and Where Are We Going?Viruses 2020; 12(9): 998 doi: 10.3390/v12090998
42
Weiqiang Gan, Jianguo Li, Chunlan Zhang, Xuefu Chen, Chaoshuang Lin, Zhiliang Gao. Efficacy of 104-week Telbivudine-based optimization strategy in patients with HBeAg-negative chronic hepatitis B virus infectionsBMC Infectious Diseases 2020; 20(1) doi: 10.1186/s12879-020-05642-y
43
Ahmed Lasfar, Andrew Zloza, Karine A. Cohen-Solal. IFN-lambda therapy: current status and future perspectivesDrug Discovery Today 2016; 21(1): 167 doi: 10.1016/j.drudis.2015.10.021
44
K. Reyes-Gordillo, R. Shah, M.R. Lakshman, R.E. Flores-Beltrán, P. Muriel. Liver Pathophysiology2017; : 687 doi: 10.1016/B978-0-12-804274-8.00049-7
45
Sajad Fakhri, Zeinab Nouri, Seyed Zachariah Moradi, Esra Küpeli Akkol, Sana Piri, Eduardo Sobarzo-Sánchez, Mohammad Hosein Farzaei, Javier Echeverría. Targeting Multiple Signal Transduction Pathways of SARS-CoV-2: Approaches to COVID-19 Therapeutic CandidatesMolecules 2021; 26(10): 2917 doi: 10.3390/molecules26102917